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ABSTRACT
Introduction Diabetes mellitus is common and growing 
in prevalence, and an increasing proportion of people 
with diabetes are living to older age. Frailty is, therefore, 
becoming an important concept in diabetes. Frailty 
is associated with older age and describes a state of 
increased susceptibility to decompensation in response to 
physiological stress. A range of measures have been used 
to quantify frailty. This systematic review aims to identify 
measures used to quantify frailty in people with diabetes 
(any type); to summarise the prevalence of frailty in 
diabetes; and to describe the relationship between frailty 
and adverse clinical outcomes in people with diabetes.
Methods and analysis Three electronic databases 
(Medline, Embase and Web of Science) will be searched 
from 2000 to November 2019 and supplemented by 
citation searching of relevant articles and hand searching 
of reference lists. Two reviewers will independently review 
titles, abstracts and full texts. Inclusion criteria include: 
(1) adults with any type of diabetes mellitus; (2) quantify 
frailty using any validated frailty measure; (3) report the 
prevalence of frailty and/or the association between frailty 
and clinical outcomes in people with diabetes; (4) studies 
that assess generic (eg, mortality, hospital admission and 
falls) or diabetes- specific outcomes (eg, hypoglycaemic 
episodes, cardiovascular events, diabetic nephropathy and 
diabetic retinopathy); (5) cross- sectional and longitudinal 
observational studies. Study quality will be assessed 
using the Newcastle–Ottawa Scale for observational 
studies. Clinical and methodological heterogeneity will be 
assessed, and a random effects meta- analysis performed 
if appropriate. Otherwise, a narrative synthesis will be 
performed.
Ethics and dissemination This manuscript describes the 
protocol for a systematic review of observational studies 
and does not require ethical approval.
PROSPERO registration number CRD42020163109.
INTRODUCTION
Diabetes mellitus (hereafter ‘diabetes’) 
describes a collection of metabolic disorders, 
with distinct pathological processes, that are 
characterised by elevated blood glucose.1 The 
most common are type 1 and type 2 diabetes. 
Type 1 diabetes is caused by insulin deficiency 
resulting from destruction of pancreatic beta 
cells, usually by an autoimmune process.2 
Type 2 diabetes describes a relative insulin 
deficiency caused by beta- cell dysfunction 
and insulin resistance of target organs.2 
Both are associated with a range of compli-
cations including macrovascular disease, 
retinopathy, nephropathy and neuropathy.3 
The prevalence of diabetes is increasing 
across the world.4 Population demographics 
are also shifting towards an ageing popula-
tion.5 Among people above the age of 65, 
the prevalence of diabetes can be as high as 
30%.6 Diabetes in older people is, therefore, 
a growing clinical and public health priority. 
One factor with important implications for 
disease management in older age is frailty.7
Frailty is a state characterised by reduced 
functional reserve across multiple physio-
logical systems.8 People living with frailty 
have impaired resolution of homaeostasis 
following physiological stressors.8 Frailty, 
therefore, carries an increased risk of a 
range of adverse health outcomes, such as 
falls, cognitive decline, hospital admission 
and mortality.9 Frailty is widely recognised 
Strengths and limitations of this study
 ► This systematic review will provide a comprehen-
sive overview of the prevalence and implications of 
frailty in people with diabetes.
 ► We will include a broad range of frailty definitions 
and clinical outcomes relevant to diabetes.
 ► There is likely to be significant heterogeneity be-
tween population characteristics and frailty defini-
tions in included studies.
 ► By including only English language articles, there 
is a chance of language bias in the results of the 
review.
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to be a multidimentional and dynamic state, associated 
with older age and with a range of non- communicable 
diseases.9 However, there is no single universally accepted 
operational definition of frailty. Rather, a wide range of 
definitions have been used in both research and clinical 
practices.10
The two dominant paradigms in the frailty literature 
are the frailty phenotype and the frailty index. The frailty 
phenotype, described by Fried et al, defines frailty as 
the presence of three or more out of five features: low 
hand grip strength, unintentional weight loss, low phys-
ical activity, exhaustion and slow walking pace.11 The 
presence of one or two of these features is classified as a 
prefrail state. The frailty index, described by Rockwood 
and Mitnitski, is based on a Cumulative Deficit Model 
of frailty, whereby frailty is identified by counting the 
number of health ‘deficits’ present in an individual.12 At 
least 30 deficits are required to construct a frailty index, 
all of which must increase in prevalence with age, be asso-
ciated with poor health and not saturate too early (ie, 
be universally present among older people).13 Both the 
frailty phenotype and the frailty index have been asso-
ciated with adverse health outcomes in a range of older 
populations; however, the populations identified as frail 
by each are different.14 Since their original description, a 
wide range of other frailty instruments, as well as adapta-
tions of the frailty index and phenotype, have been devel-
oped for both epidemiological studies and for clinical 
practice.9 10
The relationship between diabetes and frailty is 
complex. Diabetes is associated with a higher preva-
lence of frailty.15–18 Both type 1 and type 2 diabetes 
lead to microvascular and macrovascular complications 
that have important physical, cognitive and functional 
consequences, which may contribute to the develop-
ment of frailty.6 Hyperglycaemia is also recognised to 
directly impact muscle mass and quality, exacerbating 
age- related sarcopaenia and, in turn, physical function.19 
However, the association between frailty and poor func-
tional outcomes in people with diabetes is only partially 
explained by direct complications of diabetes.17 20
The importance of frailty in the context of diabetes 
is increasingly recognised in clinical guidelines.7 Specif-
ically, higher glycated haemoglobin (HbA1c) targets 
are recommended in the context of frailty, in part due 
to the increased risks associated with hypoglycaemia.21 
Despite this, up to 40% of older people with diabetes may 
be overtreated (with HbA1c<7%).22 23 Conversely, poor 
glycaemic control and associated vascular complications 
risk causing, or accelerating the progression of, frailty.24
One recent meta- analysis demonstrated a consistent 
relationship between frailty and mortality, hospitalisation 
and cardiovascular events in the context of diabetes.25 We 
are not aware of any systematic review to assess the preva-
lence of frailty in diabetes, or to consider a broader range 
of outcomes relevant to the management of diabetes.
To enhance understanding of the implications and 
management of diabetes within an ageing population, 
it is important to fully describe the association between 
diabetes and frailty. Given the risks of both over treatment 
and under treatment of diabetes in the context of frailty, 
it is important to understand the associations between 
frailty and a range of potential outcomes in diabetes. This 
includes generic outcomes such as mortality and hospital-
isation and disability and disease- specific outcomes such 
as retinopathy, neuropathy and hypoglycaemic events. An 
understanding of the range and complexity of these asso-
ciations is required to inform clinical decisions around 
treatment priorities and to underpin future research. 
This includes quantifying the prevalence of frailty in 
people with diabetes, and the impact that different frailty 
definitions might have on this prevalence. This manu-
script describes the protocol of a systematic review aiming 
to synthesise existing evidence relating to these questions.
Aims
The systematic review will aim to:
 ► Identify which frailty measures have been used 
to assess frailty in people with diabetes (any type, 
including mixed/unspecified).
 ► Quantify the prevalence of frailty among people with 
diabetes.
 ► Describe the association between frailty and both 
generic (eg, mortality) and disease- specific (eg, 
hypoglycaemia) clinical outcomes in the context of 
diabetes.
METHODS AND ANALYSIS
The review will be conducted and reported according 
to the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses statement.26 Where a meta- analysis 
is undertaken, we will report findings according to the 
Meta- analyses Of Observational Studies in Epidemiology 
checklist.
Eligibility criteria for inclusion
The eligibility criteria for this review are summarised in 
table 1 and explained in more detail below.
Population
We will include studies analysing data from people with 
any form of diabetes.
While frailty is a state associated with increasing age, 
there is evidence that frailty is identifiable in relatively 
younger people, particularly in certain contexts such as 
multimorbidity (two or more coexisting long- term condi-
tions) or in areas of high socioeconomic deprivation. 
We will, therefore, include studies of adults of any age 
(≥18 years). However, we anticipate that most studies will 
focus predominantly on ‘older’ populations.
From an initial scoping of the literature, it is likely that 
many studies describing frailty in population- based studies 
measure unspecified ‘diabetes’ rather than explicitly type 
1 or type 2 diabetes. We will, therefore, include any study 
that includes people with any type of diabetes (including 
type 1, type 2 diabetes, secondary or monogenic diabetes, 
or people with unspecified diabetes). Given that frailty is 
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a state associated with older age, and that type 2 diabetes 
is both more prevalent than type 1 diabetes and becomes 
more prevalent with age, it is likely that most (but not 
all) people with diabetes in the relevant populations will 
have type 2 diabetes. Studies of type 1, type 2 diabetes 
and those of unspecified diabetes will be considered sepa-
rately in any subsequent analysis.
We will include studies focusing purely on people with 
diabetes, or population- based studies that report results 
for people with diabetes separately.
Exposure
The ‘exposure’ of interest is frailty. Many epidemiological 
measures and clinical tools have been developed to iden-
tify frailty for research or clinical practice.10
To be eligible for inclusion, a study must use a measure 
that explicitly seeks to quantify frailty. We will include 
measures developed primarily as epidemiological tools 
(eg, the frailty phenotype and frailty index).11 12 We will 
also include measures designed primarily for clinical 
practice (eg, the Clinical Frailty Scale).27
Studies focusing solely on comorbidity (ie, no additional 
measures to identify ‘frailty’) will be excluded unless 
these are explicitly operationalised as a ‘frailty index’. In 
this case, studies would generally be expected to include 
additional deficits (such as symptoms, functional limita-
tions and laboratory measures). Studies that use a single 
parameter as a proxy for frailty (eg, grip strength alone 
and self- rated health) will be excluded.
Comparator
Studies that report the prevalence of frailty will be eligible 
for inclusion if they report the prevalence of frailty in 
diabetes only. Studies should report the number or 
proportion of participants with and without frailty (or 
with varying degrees of frailty, depending on the measure 
used).
For assessing the association between frailty and clin-
ical outcomes in the context of diabetes, studies should 
report the association between frailty and the outcome 
of interest. This may be reported either as the association 
with the presence or absence of frailty (in the case of a 
Table 1 Inclusion criteria
PECOS 
component Description
Population Adults (≥18 years old)
Diabetes (any type, including mixed or unspecified)
Exposure Frailty as assessed by any frailty measure




 ► Major adverse cardiovascular events
 ► Hospital admission
 ► Admission to long- term care facility
 ► Falls
 ► Number of clinic attendances
 ► Quality of life
 ► Disability/functional status
Diabetes specific:
 ► HbA1c (cross- sectional association, or longitudinal)
 ► Glycaemic variability
 ► Hypoglycaemic episodes
 ► Diabetic retinopathy (cross- sectional association, or longitudinal)
 ► Diabetic nephropathy (cross- sectional association, or longitudinal)
 – Include development of end- stage renal disease
 ► Diabetic foot complications (cross- sectional association or longitudinal)
 ► Treatment burden (eg, Diabetic Treatment Burden Questionnaire)
Settings Community (including care home/nursing home)
Outpatient clinic
Inpatient
Study design Cross- sectional or longitudinal
Cohort
Other exclusions Conference abstracts, letters, review articles, intervention studies and Grey literature
PECOS, Population, Exposure, Comparator, Outcome, Setting and Study design.
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binary or categorical measure) or the association between 
the degree of frailty and the outcome (in the case of a 
continuous or ordinal measure of frailty).
Outcomes
Outcomes of interest are summarised in table 1. We will 
include studies assessing any of these outcomes as long 
as the association is specifically quantified in people with 
diabetes and frailty.
Setting
We will include studies of community- dwelling patients, 
outpatient populations or hospital inpatients.
For the purposes of this review, given the focus on 
frailty, people living in long- term care facilities (eg, care 
homes and nursing homes) will be considered to be 
‘community dwelling’. Therefore, any study including, 




Medline, Embase and Web of Science (core collection) 
databases will be search using a combination of Medical 
Subject Headings and keyword searches (online supple-
mentary file 1). The terms used for the Medline search 
are shown in box 1. These terms will be adapted for the 
other databases. Searches will be from 2000 to November 
2019. The year 2000 was chosen as the start date as the 
first seminal paper operationalising the concept of frailty 
in an epidemiological study was published in 2001. Arti-
cles published prior to this date are, therefore, unlikely 
to be relevant. No language restriction will be applied 
to the search, but only English language articles will be 
included at the screening level. This language restriction 
is a pragmatic decision; however, we acknowledge that 
this may lead to a language bias in the results, potentially 
excluding relevant studies published in other languages.
Identifying additional articles
Electronic searches will be supplemented by hand 
searching reference lists of relevant articles. A citation 
search of all relevant articles will also be carried out using 
the Web of Science citation search tool.
Data collection and analysis
Selection of studies
Two reviewers, working independently, will screen all 
titles and abstracts of records identified in the database 
searches. PECOS (population, exposure, comparator, 
outcome, setting and study design) criteria outlined 
above will be used to determine eligibility. Where there 
is disagreement, studies will be retained for full- text 
screening.
Full texts of all potentially eligible studies will be 
screened independently by two reviewers. Disagreements 
about eligibility will be resolved by consensus, involving a 
third reviewer where necessary.
Data extraction
A standard data extraction form will be designed and 
piloted before being applied to each of the included 





 ► Setting (community, outpatient and residential care).
 ► Method of recruitment (eg, random sample, postal 
invitation and consecutive patients).






 ► Socioeconomic status.
 ► Comorbidities.
 ► Medications.
 ► Social circumstances (eg, living independently, 
requiring carers, family support and so on).
 ► Smoking status.
 ► Physical activity.
Diabetes details
 ► Type of diabetes.
 ► Method of confirmation (self- report, medical records 
and clinical assessment).
 ► Measure of control (eg, HbA1c).
 ► Medication (eg, proportion taking insulin, oral antidi-
abetics and so on).
 ► Presence and severity of complications (eg, retin-
opathy, nephropathy, neuropathy, ulceration and 
Charcot arthropathy).
Frailty definition
 ► Frailty measure used.
 ► Definitions for each component of the frailty measure 
(eg, cut- points used for continuous measures and 
Box 1 Medline search
1. Exp Frailty/
2. Exp Frail Elderly/
3. Frail*.tw
4. 1 or 2 or 3
5. Exp Diabetes Mellitus
6. Diabet*.tw
7. (IDDM or NIDDM or MODY or T1DM, or T2DM or T1D or T2D).tw
8. (non insulin* depend* or non insulin depend* or non insulin?de-
pend* or non insulin ?depend).tw
9. (insulin* depend* or insulin ?depend*).tw
10. 5 or 6 or 7 or 8 or 9
11. Exp Diabetes Insipidus/
12. Diabet* insipidus.tw
13. 11 or 12
14. 10 not 13
15. 4 and 14
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 ► Major adverse cardiovascular events.
 ► Hospital admission.
 ► Admission to long- term care facility.
 ► Falls.
 ► Number of clinic attendances.
 ► Quality of life.
 ► Disability/functional status
Outcomes (diabetes specific):
 ► HbA1c (cross- sectional association or longitudinal).
 ► Glycaemic variability.
 ► Hypoglycaemic episodes.
 ► Diabetic retinopathy (cross- sectional association or 
longitudinal).
 ► Diabetic nephropathy (cross- sectional association or 
longitudinal).
 ► Diabetic foot complications (cross- sectional associa-
tion or longitudinal).
 ► Treatment burden (eg, Diabetic Treatment Burden 
Questionnaire).
As we include a wide range of outcomes, it is likely that 
the way outcomes are assessed will vary depending on 
the outcome in question. Studies may also assess similar 
outcomes (eg, hospital admission) in different ways (eg, 
number of admissions over specified follow- up, time to 
first admission and presence or absence of admission 
during follow- up). For the outcomes listed above, we 
will extract data regardless of the method of assessment. 
Heterogeneity in the way outcome data were collected 
will be used to inform the approach to data synthesis (ie, 
meta- analysis vs narrative synthesis). For each outcome 
reported, we will record:
 ► The method of outcome assessment (eg, linkage to 
healthcare records, face- to- face assessment, question-
naire and so on).
 ► Method of analysis (eg, time to event, mean differ-
ence and so on).
 ► The association between frailty and the outcome (eg, 
prevalence, OR, HR and so on).
 ► Adjustment for any potential confounders.
 ► Length of follow- up over which the outcome was 
assessed.
 ► Method of analysis of competing risks when assessing 
each outcome.
Where available, we will also extract data on both rela-
tive (eg, HRs) and absolute (eg, events per 1000 people) 
associations with outcomes.
Assessment of methodological quality
The Newcastle–Ottawa Scale will be used to assess the risk 
of bias for each study (online supplementary file 2).28 This 
scale is widely used for the assessment of observational 
studies, and has frequently been adapted to the context 
of specific systematic reviews. We have adapted the criteria 
in order to be explicit about how the ‘exposure assess-
ment’ related to frailty: specifically, awarding one point 
for the use of a validated frailty assessment measure. For 
cross- sectional studies, only the first five elements of the 
scale were relevant to quality assessment (the remainder 
concerning the longitudinal assessment of outcomes). We 
will use this subsection of the Newcastle–Ottawa Scale to 
assess the quality of cross- sectional studies to allow direct 
comparability with the baseline assessments of longitu-
dinal studies (from which we will also extract data on 
frailty prevalence). In assessing the comparability of frail/
non- frail groups, age will be taken as the most important 
factor for which studies should account.
Data synthesis
The appropriate method of data synthesis will be deter-
mined after assessment of the heterogeneity of the 
included studies, in terms of population selection and 
demographics, frailty definition and method of outcome 
assessment.
With regards to the prevalence of frailty, different frailty 
measures will be considered separately (ie, we will not 
perform a meta- analysis of frailty prevalence measured 
using different scales). We will also consider community 
studies separately from studies focussing on outpatient 
clinic populations (as these may represent people with 
more severe diabetes), inpatients or people living in resi-
dential care. We will also assess the inclusion criteria and 
demographics of the sample population, with particular 
attention to age (as frailty is strongly associated with age) 
and sex (as women tend to have a higher prevalence of 
frailty than men) to determine the most appropriate 
method of synthesis. Where samples have been drawn 
from populations with a markedly different age/sex 
structure, a pooled estimate of the mean prevalence of 
frailty across these studies is unlikely to be a meaningful 
summary. Similarly, other inclusion criteria used by the 
individual studies (such as excluding ‘institutionalised’ 
people, people with cognitive impairment and people 
with impaired mobility unable to attend an assessment) 
may disproportionately impact on the estimation of frailty 
prevalence. The appropriateness, or otherwise, of a meta- 
analysis of frailty prevalence will be judged only after 
examination of these aspects of the included studies.
For the assessment of outcomes, the approach to 
synthesis will also be judged based on heterogeneity 
of the method of outcome assessment and the analytic 
approach. As above, different frailty measures will be 
considered separately.
If appropriate, we will combine these in a random effects 
meta- analysis (anticipating heterogeneity in the true asso-
ciation). As well as a pooled estimate and 95% CIs, we will 
also calculate the prediction interval to assess the range 
of plausible estimates from the observed data. Heteroge-
neity will be quantified using the I2 statistic. Where hetero-
geneity is present, we will attempt to explore potential 
sources of heterogeneity using subgroup analyses (eg, by 
method of determining frailty, age of sample population 
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and method of outcome assessment). By doing so, we 
propose to explore factors that may influence the esti-
mates reported in observational studies in the presence 
of heterogeneity, rather than provide a definitive single 
estimate.29 We will use funnel plots to assess for potential 
publication bias.
Only those studies that are judged to be suffi-
ciently comparable will be included in meta- analyses. 
For outcomes where there are too few studies, or the 
included studies are too heterogenous to permit a mean-
ingful meta- analysis (eg, in terms of outcome definition 
or method of assessing frailty), we will perform a narra-
tive synthesis of the study findings. This will report the 
methods used to identify frailty along with the prevalence 
and association with outcomes, to explore the impact of 
the method of assessment on the observed relationship. 
This will be reported alongside detail of the recruitment 
strategy, age profile and characteristics of each sample 
included.
Patient and public involvement
No patients were involved in the development of this 
review.
ETHICS AND DISSEMINATION
This systematic review will provide an overview of the 
prevalence of frailty in diabetes and the relationship 
between frailty and adverse health outcomes in people 
with diabetes.
As the prevalence of both frailty and diabetes increase, 
it will become increasingly important for clinical guide-
lines for the treatment of diabetes to explicitly consider 
the needs of people living with frailty.7 Quantifying the 
prevalence of frailty in diabetes will allow the scale of 
this challenge to be better appreciated. By including any 
reported definition of frailty within our inclusion criteria, 
this review will demonstrate which of the wide range of 
frailty instruments and measures have been used to study 
frailty in diabetes. It will also be possible to compare if 
and how prevalence and association with outcomes differs 
depending on the frailty definition used.
Given the likely heterogeneity in frailty definitions, as 
well as inherent differences in the populations studied, 
it may not be possible to undertake a meta- analysis of 
the findings of this review. If this is the case, we propose 
to conduct a detailed narrative synthesis, systematically 
describing and synthesising details of the populations 
under study as well as the details of frailty definitions used.
We also propose to search for and extract data for a 
wide range of clinical outcomes. Given the multidimen-
tional nature of frailty,8 and the vulnerability to decom-
pensation that is inherent to any frailty definition,9 it is 
likely that frailty will be associated with a range of adverse 
outcomes. The challenge in translating these associations 
into meaningful recommendations is understanding the 
balance of these risks, and how they might inform clinical 
decisions and recommendations. The balance of risks in 
diabetes, and treatment priorities, may differ depending 
on the degree of frailty experienced by an individual. The 
associations may also differ in their nature or magnitude 
depending on the method used to identify frailty. This 
review will aim to provide an overview of what is known 
about the relationship between frailty and both generic 
and disease- specific outcomes. This is likely to inform 
priorities for future research into the consequences of 
frailty in diabetes.
As this project is a systematic review, ethical approval is 
not required. Patients or the public were not involved in 
the development of this protocol.
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